[go: up one dir, main page]

DK1212050T3 - Formuleringer indeholdende tetracycliner til behandling eller forebyggelse af mucositis - Google Patents

Formuleringer indeholdende tetracycliner til behandling eller forebyggelse af mucositis

Info

Publication number
DK1212050T3
DK1212050T3 DK00974107T DK00974107T DK1212050T3 DK 1212050 T3 DK1212050 T3 DK 1212050T3 DK 00974107 T DK00974107 T DK 00974107T DK 00974107 T DK00974107 T DK 00974107T DK 1212050 T3 DK1212050 T3 DK 1212050T3
Authority
DK
Denmark
Prior art keywords
tetracycline
mucositis
prevention
treatment
formulations containing
Prior art date
Application number
DK00974107T
Other languages
Danish (da)
English (en)
Inventor
James Ronald Lawter
Stephen J Comiskey
Original Assignee
Mucosal Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mucosal Therapeutics Llc filed Critical Mucosal Therapeutics Llc
Application granted granted Critical
Publication of DK1212050T3 publication Critical patent/DK1212050T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00974107T 1999-09-14 2000-09-14 Formuleringer indeholdende tetracycliner til behandling eller forebyggelse af mucositis DK1212050T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15389299P 1999-09-14 1999-09-14
PCT/US2000/040907 WO2001019362A2 (fr) 1999-09-14 2000-09-14 Formulations permettant de traiter out de prevenir l'inflammation d'une muqueuse

Publications (1)

Publication Number Publication Date
DK1212050T3 true DK1212050T3 (da) 2007-02-26

Family

ID=22549161

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00974107T DK1212050T3 (da) 1999-09-14 2000-09-14 Formuleringer indeholdende tetracycliner til behandling eller forebyggelse af mucositis

Country Status (10)

Country Link
EP (1) EP1212050B1 (fr)
JP (1) JP2003509367A (fr)
AT (1) ATE347357T1 (fr)
AU (1) AU779450B2 (fr)
CA (1) CA2381203C (fr)
DE (1) DE60032246T2 (fr)
DK (1) DK1212050T3 (fr)
ES (1) ES2281360T3 (fr)
PT (1) PT1212050E (fr)
WO (1) WO2001019362A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508075A (ja) * 2002-10-07 2006-03-09 オラファーマ， インコーポレイテッド 粘膜付着性テトラサイクリン製剤
KR20130122988A (ko) 2005-03-14 2013-11-11 와이어쓰 엘엘씨 티게사이클린 조성물 및 이의 제조방법
AR061485A1 (es) * 2006-06-15 2008-08-27 Serenex Inc Composiciones estabilizadas de tetraciclina
TW200812645A (en) * 2006-06-15 2008-03-16 Serenex Inc Tetracycline package formulations
AU2009282659A1 (en) * 2008-08-18 2010-02-25 Nanotherapeutics, Inc. Topical hydrogel composition
WO2010033800A2 (fr) * 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Formulations stabilisant la tétracycline
US11202788B2 (en) 2019-08-22 2021-12-21 Nanopharmaceutics, Inc. Topical doxycycline hydrogel with improved long-term stability

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650665A (en) * 1985-02-08 1987-03-17 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
WO1994027579A1 (fr) * 1993-05-24 1994-12-08 Ribogene, Inc. Composition pour le traitement d'ulceres
US5827840A (en) * 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
IL122084A (en) * 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
US5981499A (en) * 1998-02-20 1999-11-09 Atlantic Biomed Corporation Lesion-directed antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa
US6458777B1 (en) * 1998-03-13 2002-10-01 Mucosal Therapeutics Llc Methods and compositions for treating and preventing mucositis
US6432934B1 (en) * 1998-08-06 2002-08-13 Advanced Vision Research Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease

Also Published As

Publication number Publication date
EP1212050B1 (fr) 2006-12-06
JP2003509367A (ja) 2003-03-11
CA2381203C (fr) 2008-12-02
PT1212050E (pt) 2007-03-30
CA2381203A1 (fr) 2001-03-22
ES2281360T3 (es) 2007-10-01
AU1252501A (en) 2001-04-17
WO2001019362A2 (fr) 2001-03-22
ATE347357T1 (de) 2006-12-15
WO2001019362A3 (fr) 2001-12-13
AU779450B2 (en) 2005-01-27
DE60032246D1 (de) 2007-01-18
EP1212050A2 (fr) 2002-06-12
DE60032246T2 (de) 2007-06-21

Similar Documents

Publication Publication Date Title
MX9200992A (es) Composicion farmaceutica que tiene como ingrediente activo 3-[2-(dimetilamino)etil]-n-metil-1h-indol-5-metanosulfonamida y procedimiento para su preparacion.
TR200200562T2 (tr) Vücutta kontrollü şekilde salgılanabilen ve nahoş tadı önleyebilen ağızdan alınmaya mahsus farmasötik bileşimler
DE60027463D1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
TR199802108T2 (xx) �bandronat i�eren oral farmas�tik bir form�lasyon.
DE60024491D1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
RU93053489A (ru) Фармацевтическая композиция противоалкогольного, стимулирующего энергетический обмен, кислотообразующую и секреторную функцию слизистой желудка, радиопротекторного и противохолерного действия
AR031067A1 (es) Un sachet; una tableta y un polvo efervescente de administracion oral para prevenir y tratar disfunciones sexuales y el uso de l-arginina y/o yohimbina y/o una sal farmaceuticamente aceptable de la misma.
PL373276A1 (en) Trans-epicutaneous administration form for treating restless leg syndrome
SE0102843D0 (sv) Stabilized oral pharmaceutical composition containing lodide and lodate and method
DK1212050T3 (da) Formuleringer indeholdende tetracycliner til behandling eller forebyggelse af mucositis
MY131488A (en) Low dose liquid entecavir formulations and use
CA2417935A1 (fr) Medicament anti-inflammatoire
ES2186207T3 (es) Metodo para preparacion de formulaciones farmaceuticas.
CA2385755A1 (fr) Prevention du cancer colorectal
RU95120362A (ru) Синергическая композиция, содержащая бензимидазоловый противогельмитный агент и метилендиоксифенильное соединение, способ лечения, применение бензимидазола или его пролекарства и метилендиоксифенильного синергиста для получения противогельмитной композиции
TR200103144T2 (tr) Yeni bileşikler
SE0103528D0 (sv) Topiska kompositioner med förstärkt effekt
WO2004032843A3 (fr) Formulations de tetracycline muco-adhesives
WO2004000223A3 (fr) Preparations se desintegrant rapidement et destinees au traitement ou a la prevention de l'inflammation d'une muqueuse
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
AR037543A1 (es) Metodo para la terapia del cancer y composicion farmaceutica
JPH1129493A5 (fr)
RU2003125096A (ru) Психостимулирующее средство
NO20050933L (no) Pravastatin farmasoytiske formuleringer og fremgangsmater for anvendelse derav